{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:06:08Z","timestamp":1792047968853,"version":"4.4.0"},"reference-count":71,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Evidence-based, patient-centered treatment for alcohol use disorder (AUD) can include pharmacotherapy with naltrexone, acamprosate, or disulfiram; however, these medications are rarely used. Medicaid managed care plans (MCPs) manage health services for nearly 80% of Medicaid enrollees and are the largest payer for addiction treatment services. Little is known about Medicaid MCP policies for AUD medications.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To describe Medicaid MCPs\u2019 coverage and management of acamprosate, naltrexone, and disulfiram for AUD and examine associations of plan characteristics and state policies with medication coverage.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this cross-sectional study, a content analysis was performed of 2021 insurance benefit data for 241 comprehensive Medicaid MCPs in states using Medicaid managed care, as well as secondary sources. Data were analyzed from May to August 2024.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Medicaid MCP-reported medication coverage and utilization management requirements (eg, prior authorization, quantity limit requirements) for acamprosate, disulfiram, and oral and injectable naltrexone together and for each medication separately. Independent variables included plan characteristics (profit status, market share) and the state policy environment in which plans are embedded (Section 1115 substance use disorder waiver, state-defined preferred drug list). Regressions examined associations of plan characteristics and state policies with medication coverage.<\/jats:p><\/jats:sec>Results<\/jats:title>In this cross-sectional content analysis of 241 comprehensive Medicaid MCPs in 2021, 217 (90.0%) covered at least 1 medication for AUD: 132 (54.7%) covered acamprosate, 203 (84.2%) covered oral naltrexone, 175 (72.6%) covered injectable naltrexone, 152 (63.0%) covered disulfiram, and 103 (42.7%) covered all 4 medications. Prior authorization and quantity limits were rarely applied, except for injectable naltrexone, for which 75 plans (42.8%) imposed at least 1 of these utilization management requirements.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study suggests that efforts to expand AUD medication prescribing may be limited by gaps in health insurance coverage. Medicaid MCPs and states can support AUD medication utilization by covering these medications without applying utilization management strategies.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.0695","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:01:52Z","timestamp":1741878112000},"page":"e250695","source":"Crossref","is-referenced-by-count":13,"title":["Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans"],"prefix":"10.1001","volume":"8","author":[{"given":"Maureen T.","family":"Stewart","sequence":"first","affiliation":[{"name":"Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"},{"name":"Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sage R.","family":"Feltus","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"},{"name":"Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Acevedo","sequence":"additional","affiliation":[{"name":"Booz Allen Hamilton Inc, McLean, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy Parks","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bratberg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Research, University of Rhode Island College of Pharmacy, Kingston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance M.","family":"Horgan","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Hodgkin","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Sayko","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"8","key":"zoi250056r4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.15585\/mmwr.mm7308a1","article-title":"Deaths from Excessive Alcohol Use\u2014United States, 2016\u20132021.","volume":"73","author":"Esser","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"zoi250056r7","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.3390\/ijerph20085587","article-title":"Racial and ethnic disparities in alcohol-attributed deaths in the United States, 1999\u20132020.","volume":"20","author":"Karaye","year":"2023","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"zoi250056r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26346","article-title":"Trends in alcohol-related deaths by sex in the US, 1999-2020.","volume":"6","author":"Karaye","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi250056r9","doi-asserted-by":"publisher","DOI":"10.35946\/arcr.v40.2.01","author":"White","year":"2020","journal-title":"Alcohol Res"},{"issue":"2","key":"zoi250056r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21451","article-title":"Trends in alcohol-induced deaths in the United States, 2000-2016.","volume":"3","author":"Spillane","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi250056r11","doi-asserted-by":"publisher","DOI":"10.35946\/arcr.v41.1.07","author":"Mason","year":"2021","journal-title":"Alcohol Res"},{"issue":"6","key":"zoi250056r13","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jhep.2020.12.004","article-title":"Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.","volume":"74","author":"Avance\u00f1a","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"zoi250056r14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/00048674231201541","article-title":"Economic evaluations of alcohol pharmacotherapy: systematic review of economic evaluations of pharmacotherapy for the treatment of alcohol use disorder.","volume":"58","author":"Higginbotham","year":"2024","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"zoi250056r15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.","volume":"175","author":"Reus","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"8","key":"zoi250056r16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review.","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"zoi250056r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder.","volume":"5","author":"Vannier","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"18","key":"zoi250056r18","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"zoi250056r19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"issue":"6","key":"zoi250056r20","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1530-0277.1992.tb00695.x","article-title":"Techniques to enhance compliance with disulfiram.","volume":"16","author":"Allen","year":"1992","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"zoi250056r21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: a half of a century later.","volume":"26","author":"Suh","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"zoi250056r22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"zoi250056r23","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000093","article-title":"Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis.","volume":"7","author":"Rabiee","year":"2023","journal-title":"Hepatol Commun"},{"issue":"7","key":"zoi250056r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1722","article-title":"Meeting the needs of Medicaid beneficiaries with substance use disorders in managed care.","volume":"3","author":"Donohue","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"7","key":"zoi250056r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1771","article-title":"Performance metrics of substance use disorder care among Medicaid enrollees in New York, New York.","volume":"3","author":"Alegr\u00eda","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"7","key":"zoi250056r32","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1377\/hlthaff.2023.01023","article-title":"Most states allow Medicaid managed care plans discretion to restrict substance use disorder treatment benefits.","volume":"43","author":"Peterson","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"zoi250056r34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3132","article-title":"Association of formulary prior authorization policies with buprenorphine-naloxone prescriptions and hospital and emergency department use among Medicare beneficiaries.","volume":"3","author":"Mark","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi250056r35","first-page":"e52","article-title":"Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid.","volume":"20","author":"Seabury","year":"2014","journal-title":"Am J Manag Care"},{"issue":"5","key":"zoi250056r37","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/1077558708316930","article-title":"Do for-profit health plans restrict access to care under Medicaid managed care?","volume":"65","author":"Long","year":"2008","journal-title":"Med Care Res Rev"},{"issue":"12","key":"zoi250056r38","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jamainternmed.2020.5408","article-title":"Association of Medicaid-focused or commercial Medicaid managed care plan type with outpatient and acute care.","volume":"180","author":"Swaminathan","year":"2020","journal-title":"JAMA Intern Med"},{"key":"zoi250056r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2024.209357","article-title":"Substance use disorder treatment carve outs in Medicaid managed care.","volume":"161","author":"Silverman","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"3","key":"zoi250056r40","first-page":"85","article-title":"What happens when employers switch from a \u201ccarve-out\u201d to a \u201ccarve-in\u201d model of managed behavioral health?","volume":"22","author":"Ettner","year":"2019","journal-title":"J Ment Health Policy Econ"},{"key":"zoi250056r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109847","article-title":"The effect of the Drug Medi-Cal Organized Delivery System 1115 demonstration waiver on substance use disorder treatment access: evidence from California.","volume":"246","author":"Bass","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi250056r42","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1186\/s12913-022-07955-x","article-title":"Association between dispensing of low-value oral albuterol and removal from Medicaid preferred drug lists.","volume":"22","author":"Volerman","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"zoi250056r45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-031323-115847","author":"Koob","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"zoi250056r52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13722-020-00194-7","article-title":"How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? an overview for clinicians.","volume":"15","author":"Bachhuber","year":"2020","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"zoi250056r54","first-page":"229","article-title":"Focus on: ethnicity and the social and health harms from drinking.","volume":"35","author":"Chartier","year":"2013","journal-title":"Alcohol Res"},{"issue":"1","key":"zoi250056r55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/epirev\/mxr018","article-title":"The role of race\/ethnicity in alcohol-attributable injury in the United States.","volume":"34","author":"Keyes","year":"2012","journal-title":"Epidemiol Rev"},{"issue":"6","key":"zoi250056r56","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1111\/acer.12398","article-title":"Racial\/ethnic disparities in alcohol-related problems: differences by gender and level of heavy drinking.","volume":"38","author":"Witbrodt","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"zoi250056r57","first-page":"225","article-title":"Racial and ethnic disparities in liver transplantation for alcohol-associated liver diseases in the United States.","volume":"108","author":"Cotter","year":"2024","journal-title":"Transplantation"},{"issue":"1","key":"zoi250056r58","first-page":"83","article-title":"Associations between socioeconomic factors and alcohol outcomes.","volume":"38","author":"Collins","year":"2016","journal-title":"Alcohol Res"},{"issue":"6","key":"zoi250056r59","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1016\/S2468-2667(20)30052-9","article-title":"The role of alcohol use and drinking patterns in socioeconomic inequalities in mortality: a systematic review.","volume":"5","author":"Probst","year":"2020","journal-title":"Lancet Public Health"},{"issue":"4","key":"zoi250056r63","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/acer.13346","article-title":"Liver injury and endotoxemia in male and female alcohol-dependent individuals admitted to an alcohol treatment program.","volume":"41","author":"Kirpich","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"zoi250056r66","first-page":"78","article-title":"Disparities in alcohol treatment use at the intersection of race, ethnicity, gender and insurance.","volume":"46","author":"Acevedo","year":"2025","journal-title":"Subst Use Addctn J"},{"issue":"1","key":"zoi250056r67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1176\/ps.2009.60.1.35","article-title":"Impact of substance disorders on medical expenditures for Medicaid beneficiaries with behavioral health disorders.","volume":"60","author":"Clark","year":"2009","journal-title":"Psychiatr Serv"},{"issue":"11","key":"zoi250056r68","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1176\/ps.2010.61.11.1074","article-title":"Regulating a health insurance exchange: implications for individuals with mental illness.","volume":"61","author":"McGuire","year":"2010","journal-title":"Psychiatr Serv"},{"issue":"3","key":"zoi250056r70","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3387","article-title":"Outcomes after initiation of medications for alcohol use disorder at hospital discharge.","volume":"7","author":"Bernstein","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi250056r71","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1097\/ADM.0000000000000918","article-title":"First-line medications for the outpatient treatment of alcohol use disorder: a systematic review of perceived barriers.","volume":"16","author":"Gregory","year":"2022","journal-title":"J Addict Med"},{"key":"zoi250056r61","volume-title":"Poverty in States and Metropolitan Areas: 2022","author":"Benson","year":"2023"},{"key":"zoi250056r1","unstructured":"Facts about excessive drinking. Centers for Disease Control and Prevention. July 11, 2022. Accessed February 12, 2024. https:\/\/www.cdc.gov\/drinklessbeyourbest\/excessivedrinking.html"},{"key":"zoi250056r2","unstructured":"2023 National Survey on Drug Use and Health (NSDUH) releases. Substance Abuse and Mental Health Services Administration. July 30, 2024. Accessed August 29, 2024. https:\/\/www.samhsa.gov\/data\/release\/2023-national-survey-drug-use-and-health-nsduh-releases#detailed-tables"},{"key":"zoi250056r3","unstructured":"Global status report on alcohol and health 2018. World Health Organization. Accessed July 25, 2024. https:\/\/iris.who.int\/handle\/10665\/274603"},{"key":"zoi250056r5","unstructured":"Saunders? H, Rudowitz? R. A look at the latest alcohol death data and change over the last decade. KFF. May 23, 2024. Accessed June 20, 2024. https:\/\/www.kff.org\/mental-health\/issue-brief\/a-look-at-the-latest-alcohol-death-data-and-change-over-the-last-decade\/"},{"key":"zoi250056r6","unstructured":"Alcohol-related emergencies and deaths in the United States. National Institute on Alcohol Abuse and Alcoholism. 2024. Accessed July 25, 2024. https:\/\/www.niaaa.nih.gov\/alcohols-effects-health\/alcohol-topics\/alcohol-facts-and-statistics\/alcohol-related-emergencies-and-deaths-united-states"},{"key":"zoi250056r12","unstructured":"Recommend evidence-based treatment: know the options. National Institute on Alcohol Abuse and Alcoholism. 2024. Accessed July 25, 2024. https:\/\/www.niaaa.nih.gov\/health-professionals-communities\/core-resource-on-alcohol\/recommend-evidence-based-treatment-know-options"},{"key":"zoi250056r24","unstructured":"Acamprosate calcium (generic for Campral). Mark Cuban Cost Plus Drug Company. Accessed June 20, 2024. https:\/\/costplusdrugs.com\/medications\/acamprosate-calcium-333mg-tablet-delayed-release-campral\/"},{"key":"zoi250056r25","unstructured":"Naltrexone HCl (generic for ReVia). Mark Cuban Cost Plus Drug Company. Accessed June 20, 2024. https:\/\/costplusdrugs.com\/medications\/NaltrexoneHCl-50mg-Tablet\/"},{"key":"zoi250056r26","unstructured":"Disulfiram (generic for Antabuse). Mark Cuban Cost Plus Drug Company. Accessed June 20, 2024. https:\/\/costplusdrugs.com\/medications\/disulfiram-250mg-tablet-antabuse\/"},{"key":"zoi250056r27","unstructured":"Vivitrol prices, coupons, copay cards & patient assistance. Drugs.com. Accessed June 20, 2024. https:\/\/www.drugs.com\/price-guide\/vivitrol"},{"key":"zoi250056r28","unstructured":"State health facts. Total Medicaid MCO enrollment. KFF. August 4, 2022. Accessed August 11, 2023. https:\/\/www.kff.org\/other\/state-indicator\/total-medicaid-mco-enrollment\/"},{"key":"zoi250056r30","unstructured":"Hinton? E, Rudowitz? R, Stolyar? L, Singer? N. 10 Things to know about Medicaid managed care. KFF. 2020. Accessed February 22, 2021. https:\/\/www.kff.org\/medicaid\/issue-brief\/10-things-to-know-about-medicaid-managed-care\/"},{"key":"zoi250056r33","unstructured":"IssueBrief. Prior authorization in Medicaid. Medicaid and CHIP Payment and Access Commission (MACPAC). Published online August 2024. Accessed December 13, 2024. https:\/\/www.macpac.gov\/wp-content\/uploads\/2024\/08\/Prior-Authorization-in-Medicaid.pdf"},{"key":"zoi250056r36","unstructured":"Report to Congress: utilization management of medication-assisted treatment in Medicaid. Medicaid and CHIP Payment and Access Commission (MACPAC). October 2019. Accessed September 25, 2024. https:\/\/www.macpac.gov\/wp-content\/uploads\/2019\/10\/Report-to-Congress-Utilization-Management-of-Medication-Assisted-Treatment-in-Medicaid.pdf"},{"key":"zoi250056r43","unstructured":"Providers clinical support system\u2014medications for alcohol use disorders (PCSS-MAUD). Substance Abuse and Mental Health Services Administration. February 13, 2024. Accessed June 6, 2024. https:\/\/www.samhsa.gov\/medications-alcohol-use-disorders-pcss-maud"},{"key":"zoi250056r44","unstructured":"Explore the new FY 2024-25 agency priority goals. Performance.gov. December 4, 2023. Accessed June 6, 2024. https:\/\/web.archive.org\/web\/20231215235249\/https:\/\/www.performance.gov\/blog\/fy2024-25-agency-priority-goals-release\/"},{"key":"zoi250056r46","unstructured":"Enrollment report. 2021. Centers for Medicare & Medicaid Services. Accessed July 23, 2024. https:\/\/www.medicaid.gov\/medicaid\/managed-care\/enrollment-report\/index.html"},{"key":"zoi250056r47","unstructured":"Health plan report cards. National Committee for Quality Assurance. 2021. Accessed May 17, 2024. https:\/\/reportcards.ncqa.org\/health-plans"},{"key":"zoi250056r48","unstructured":"December 2021 and January 2022 Medicaid and CHIP enrollment trends snapshot. Centers for Medicare & Medicaid Services. 2021. Accessed December 8, 2023. https:\/\/www.medicaid.gov\/sites\/default\/files\/2022-04\/dec-2021-jan-2022-medicaid-chip-enrollment-trend-snapshot_0.pdf"},{"key":"zoi250056r49","unstructured":"Section 1115 demonstrations. Centers for Medicare & Medicaid Services. 2021. Accessed April 8, 2024. https:\/\/www.medicaid.gov\/medicaid\/section-1115-demonstrations\/index.html"},{"key":"zoi250056r50","unstructured":"2021-2022 NSDUH: model-based estimated prevalence for states. Substance Abuse and Mental Health Services Administration. February 15, 2024. Accessed June 7, 2024. https:\/\/www.samhsa.gov\/data\/report\/2021-2022-nsduh-state-prevalence-estimates"},{"key":"zoi250056r51","unstructured":"SUPPORT for Patients and Communities Act, HR 6, 115th Cong (2017-2018). Pub. L. 115\u2013271, \u00a71(a), Oct. 24, 2018, 132 Stat. 3894. Accessed February 5, 2025. https:\/\/www.congress.gov\/bill\/115th-congress\/house-bill\/6\/text"},{"key":"zoi250056r53","unstructured":"Substance Abuse and Mental Health Services Administration. Chapter 2\u2014acamprosate. In: Incorporating Alcohol Pharmacotherapies Into Medical Practice. Substance Abuse and Mental Health Services Administration; 2009. Accessed July 22, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64035\/"},{"key":"zoi250056r60","unstructured":"Population distribution by race\/ethnicity. KFF. 2021. Accessed August 2, 2024. https:\/\/www.kff.org\/other\/state-indicator\/distribution-by-raceethnicity\/"},{"key":"zoi250056r62","unstructured":"Urban and rural. 2020. Accessed August 30, 2024. United States Census Bureau. https:\/\/www.census.gov\/programs-surveys\/geography\/guidance\/geo-areas\/urban-rural.html"},{"key":"zoi250056r64","unstructured":"Women\u2019s health insurance coverage. KFF. December 13, 2023. Accessed August 7, 2024. https:\/\/www.kff.org\/womens-health-policy\/fact-sheet\/womens-health-insurance-coverage\/"},{"key":"zoi250056r65","unstructured":"Medicaid enrollees by sex. KFF. Accessed August 30, 2024. https:\/\/www.kff.org\/medicaid\/state-indicator\/medicaid-enrollees-by-sex\/"},{"key":"zoi250056r69","unstructured":"Providers Clinical Support System\u2014Medications for Alcohol Use Disorder. Accessed January 28, 2025. https:\/\/www.pcss-maud.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2831362\/stewart_2025_oi_250056_1741214265.23069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:02:10Z","timestamp":1741878130000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2831362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.0695","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}